Chang et al. discovered that there was a higher level of HIF-1α in the proliferative phase of hemangioma than that in the regress phase; but a decrease of HIF-1α emerged from the serum of hemangioma patients after systemic sclerotherapy [46]. Here, HIF1A is linked to hemangioma.